Detalles de la búsqueda
1.
Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.
Bioorg Med Chem
; 22(21): 6071-88, 2014 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25267004
2.
Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti-seizure medication.
Epilepsia Open
; 8(3): 834-845, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37052238
3.
Silinanyl Rhodamines and Silinanyl Fluoresceins for Super-Resolution Microscopy.
J Phys Chem B
; 125(31): 8703-8711, 2021 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34328341
4.
Synthesis of 1-arylpiperazyl-2-phenylcyclopropanes designed as antidopaminergic agents: cyclopropane-based conformationally restricted analogs of haloperidol.
Bioorg Med Chem
; 16(19): 8875-81, 2008 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18793859
5.
Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
J Med Chem
; 49(18): 5587-96, 2006 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-16942032
6.
Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
J Med Chem
; 46(10): 1980-8, 2003 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-12723960
7.
Development of versatile cis- and trans-dicarbon-substituted chiral cyclopropane units: synthesis of (1S,2R)- and (1R,2R)-2-aminomethyl-1-(1H-imidazol-4-yl)cyclopropanes and their enantiomers as conformationally restricted analogues of histamine.
J Org Chem
; 67(5): 1669-77, 2002 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-11871901
8.
Highly stereoselective grignard addition to cis-substituted C-cyclopropylaldonitrones. The bisected s-trans transition state can be stabilized effectively by the Lewis acid-coordination.
J Org Chem
; 69(26): 9143-50, 2004 Dec 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-15609948
9.
Construction of a cis-cyclopropane via reductive radical decarboxylation. Enantioselective synthesis of cis- and trans-1-arylpiperazyl-2-phenylcyclopropanes designed as antidopaminergic agents.
J Org Chem
; 68(24): 9255-62, 2003 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-14629144
10.
A systematic study of the hydride reduction of cyclopropyl ketones with structurally simplified substrates. highly stereoselective reductions of trans-substituted cyclopropyl ketones via the bisected s-cis conformation.
J Org Chem
; 68(9): 3511-21, 2003 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-12713354
11.
Conformational analysis of the NMDA receptor antagonist (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) designed by a novel conformational restriction method based on the structural feature of cyclopropane ring.
Chem Pharm Bull (Tokyo)
; 50(7): 966-8, 2002 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12130856
12.
Synthesis of derivatives of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) modified at the 1-aromatic moiety as novel NMDA receptor antagonists: the aromatic group is essential for the activity.
Bioorg Med Chem
; 10(12): 3829-48, 2002 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-12413836
13.
Synthesis of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) derivatives modified at the carbamoyl moiety as a new class of NMDA receptor antagonists.
Bioorg Med Chem
; 10(6): 1777-91, 2002 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-11937336
Resultados
1 -
13
de 13
1
Próxima >
>>